Trial Profile
A Phase III Multicenter Extension Study Evaluating the Safety of 25 and 50 mg Proellex in the Treatment of Women Who Have Completed ZPU-301, ZPU-302, ZPU-303, or ZPU-304
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2014
Price :
$35
*
At a glance
- Drugs Telapristone (Primary)
- Indications Uterine leiomyoma
- Focus Adverse reactions
- Sponsors Repros Therapeutics
- 20 Feb 2010 New trial record